Guardant Health Inc (Guardant Health) is a precision oncology company that commercializes novel therapeutics for cancer. The company develops proprietary digital sequencing technology used to detect individual genomic alterations. It offers Guardant360, a tool for early cancer detection used during cancer treatment for residual disease monitoring and also recurrence monitoring. The company test platform includes GuardantOMNI, GuardantINFINITY and GuardantINFORM. Guardant Health also develops a cloud-based information platform for liquid biopsy-based genomic testing in cancer treatments. The company has operations in the Netherlands, Japan, Singapore, and the US. Guardant Health is headquartered in Pao Alto, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Guardant Health Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Guardant Health Inc Company Overview
- Guardant Health Inc Company Snapshot
- Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview
- Guardant Health Inc - Pipeline Analysis Overview
- Guardant Health Inc - Key Facts
- Guardant Health Inc - Major Products and Services
- Guardant Health Inc Pipeline Products by Development Stage
- Guardant Health Inc Ongoing Clinical Trials by Trial Status
- Guardant Health Inc Pipeline Products Overview
- Anti-RSP03 Antibody Based Blood Test
- Anti-RSP03 Antibody Based Blood Test Product Overview
- cfDNA Diagnostic Assay
- cfDNA Diagnostic Assay Product Overview
- Gene-Based Test - Lung Cancer
- Gene-Based Test - Lung Cancer Product Overview
- Guardant Reveal Blood Test - Multiple Cancers
- Guardant Reveal Blood Test - Multiple Cancers Product Overview
- Guardant Reveal Blood Test - Multiple Cancers Clinical Trial
- Guardant Shield Lung Test
- Guardant Shield Lung Test Product Overview
- Guardant Shield Lung Test Clinical Trial
- Guardant360 CDx Liquid Biopsy Test - Zongertinib
- Guardant360 CDx Liquid Biopsy Test - Zongertinib Product Overview
- Guardant360 CDx Test - Taletrectinib
- Guardant360 CDx Test - Taletrectinib Product Overview
- Guardant360 CDx Test - Tepotinib
- Guardant360 CDx Test - Tepotinib Product Overview
- Guardant360 Companion Diagnostic Assay - Glesatinib
- Guardant360 Companion Diagnostic Assay - Glesatinib Product Overview
- Guardant360 Liquid Biopsy Test
- Guardant360 Liquid Biopsy Test Product Overview
- Guardant360 Smart Liquid Biopsy App
- Guardant360 Smart Liquid Biopsy App Product Overview
- Guardant360 TissueNext - Expanded Version
- Guardant360 TissueNext - Expanded Version Product Overview
- Guardant360 TissueNext PD-L1 Test
- Product Status
- GuardantOMNI Test - Imfinzi
- GuardantOMNI Test - Imfinzi Product Overview
- LUNAR-2 Assay
- LUNAR-2 Assay Product Overview
- LUNAR-2 Assay Clinical Trial
- Next-Generation CGP Tissue Assay
- Next-Generation CGP Tissue Assay Product Overview
- Shield CRC + Lung
- Shield CRC + Lung Product Overview
- Shield Multi-Cancer
- Shield Multi-Cancer Product Overview
- Smart Liquid Biopsy
- Smart Liquid Biopsy Product Overview
- Guardant Health Inc - Key Competitors
- Guardant Health Inc - Key Employees
- Guardant Health Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Guardant Health Inc, Recent Developments
- Jun 04, 2025: Guardant Health's MCD test earns FDA breakthrough designation
- Jun 02, 2025: National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening
- Jun 02, 2025: Serena-6 Phase III Trial Demonstrates Clinical Value of GUARDANT360 CDX Test To Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer
- May 31, 2025: In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions
- May 27, 2025: Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test
- May 22, 2025: Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting
- May 20, 2025: Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer
- May 20, 2025: Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer
- May 08, 2025: Guardant Health to Participate in Upcoming Investor Conferences
- Apr 29, 2025: Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview
- Guardant Health Inc Pipeline Products by Equipment Type
- Guardant Health Inc Pipeline Products by Indication
- Guardant Health Inc Ongoing Clinical Trials by Trial Status
- Guardant Health Inc, Key Facts
- Guardant Health Inc, Major Products and Services
- Guardant Health Inc Number of Pipeline Products by Development Stage
- Guardant Health Inc Pipeline Products Summary by Development Stage
- Guardant Health Inc Ongoing Clinical Trials by Trial Status
- Guardant Health Inc Ongoing Clinical Trials Summary
- Anti-RSP03 Antibody Based Blood Test - Product Status
- Anti-RSP03 Antibody Based Blood Test - Product Description
- cfDNA Diagnostic Assay - Product Status
- cfDNA Diagnostic Assay - Product Description
- Gene-Based Test - Lung Cancer - Product Status
- Gene-Based Test - Lung Cancer - Product Description
- Guardant Reveal Blood Test - Multiple Cancers - Product Status
- Guardant Reveal Blood Test - Multiple Cancers - Product Description
- Guardant Reveal Blood Test - Multiple Cancers - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Guardant Shield Lung Test - Product Status
- Guardant Shield Lung Test - Product Description
- Guardant Shield Lung Test - Screening for High Frequency Malignant Disease
- Guardant360 CDx Liquid Biopsy Test - Zongertinib - Product Status
- Guardant360 CDx Liquid Biopsy Test - Zongertinib - Product Description
- Guardant360 CDx Test - Taletrectinib - Product Status
- Guardant360 CDx Test - Taletrectinib - Product Description
- Guardant360 CDx Test - Tepotinib - Product Status
- Guardant360 CDx Test - Tepotinib - Product Description
- Guardant360 Companion Diagnostic Assay - Glesatinib - Product Status
- Guardant360 Companion Diagnostic Assay - Glesatinib - Product Description
- Guardant360 Liquid Biopsy Test - Product Status
- Guardant360 Liquid Biopsy Test - Product Description
- Guardant360 Smart Liquid Biopsy App - Product Status
- Guardant360 Smart Liquid Biopsy App - Product Description
- Guardant360 TissueNext - Expanded Version - Product Status
- Guardant360 TissueNext - Expanded Version - Product Description
- Product Status
- Guardant360 TissueNext PD-L1 Test - Product Description
- GuardantOMNI Test - Imfinzi - Product Status
- GuardantOMNI Test - Imfinzi - Product Description
- LUNAR-2 Assay - Product Status
- LUNAR-2 Assay - Product Description
- LUNAR-2 Assay - Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
- Next-Generation CGP Tissue Assay - Product Status
- Next-Generation CGP Tissue Assay - Product Description
- Shield CRC + Lung - Product Status
- Shield CRC + Lung - Product Description
- Shield Multi-Cancer - Product Status
- Shield Multi-Cancer - Product Description
- Smart Liquid Biopsy - Product Status
- Smart Liquid Biopsy - Product Description
- Guardant Health Inc, Key Employees
- Guardant Health Inc, Subsidiaries
- Glossary
- Guardant Health Inc Pipeline Products by Equipment Type
- Guardant Health Inc Pipeline Products by Development Stage
- Guardant Health Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- NantHealth Inc
- InVitae Corp
- Roche Molecular Systems Inc
- Qiagen NV
- Novartis Pharmaceuticals Corp
- BioGenex Laboratories Inc
- Illumina Inc
- ElSohly Laboratories Inc
- Thermo Fisher Scientific Inc
- Natera Inc
